David Burger
Overview
Explore the profile of David Burger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
1518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Wekken-Pas L, Weiss F, Simon-Zuber C, Sebisch R, Wiese C, van Leeuwen E, et al.
Clin Infect Dis
. 2025 Jan;
PMID: 39786548
No abstract available.
2.
Jongen V, Wit F, Boyd A, van Eeden A, Brouwer A, Soetekouw R, et al.
Lancet HIV
. 2025 Jan;
12(1):e40-e50.
PMID: 39779044
Background: Real-world data showing the long-term effectiveness of long-acting injectable cabotegravir and rilpivirine are scarce. We assessed the effectiveness of cabotegravir and rilpivirine in all individuals who switched to cabotegravir...
3.
Schomaker M, Denti P, Bienczak A, Burger D, Diaz I, Gibb D, et al.
Pharmacoepidemiol Drug Saf
. 2024 Dec;
33(12):e70051.
PMID: 39627164
Background: Determining a therapeutic window for maintaining antiretroviral drug concentrations within an appropriate range is required for identifying effective dosing regimens. The limits of this window are typically calculated using...
4.
Burger D, de Jong L, van Dijk D, Knibbe C, Ter Heine R, Smolders E, et al.
J Clin Pharmacol
. 2024 Nov;
PMID: 39569800
No abstract available.
5.
Burger D, Wttewaal E, Oosterhof P, Stalenhoef J
AIDS
. 2024 Aug;
38(11):1728-1729.
PMID: 39088831
No abstract available.
6.
van der Wekken-Pas L, Weiss F, Simon-Zuber C, Sebisch R, Wiese C, van Leeuwen E, et al.
Clin Infect Dis
. 2024 May;
79(6):1468-1471.
PMID: 38703388
This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower....
7.
van Welzen B, Burger D, Wensing A
Clin Infect Dis
. 2024 Mar;
80(1):231-232.
PMID: 38482713
No abstract available.
8.
Ambrosioni J, Diaz N, Marzolini C, Dragovic G, Imaz A, Calcagno A, et al.
Infect Dis Ther
. 2024 Feb;
13(3):609-617.
PMID: 38372897
Introduction: The objective was to characterize real-world outcomes of drug-drug interactions (DDIs) between antiretrovirals (ARVs) and other drugs, including over-the-counter medications (OTC), and treatment outcomes in clinical practice. Methods: www.clinicalcasesDDIs.com...
9.
van der Wekken-Pas L, Nassiwa S, Malaba T, Lamorde M, Myer L, Waitt C, et al.
AIDS
. 2024 Jan;
38(7):975-981.
PMID: 38277390
Background: Both dolutegravir and efavirenz are known to be effective in pregnancy and postpartum to prevent vertical transmission of HIV and to maintain maternal health. Both drugs have also been...
10.
van Welzen B, Van Lelyveld S, Ter Beest G, Gisolf J, Geerlings S, Prins J, et al.
Clin Infect Dis
. 2024 Jan;
79(1):189-195.
PMID: 38207125
Background: Long-acting (LA) injectable therapy with cabotegravir (CAB) and rilpivirine (RPV) is currently used as maintenance treatment for human immunodeficiency virus type 1, and has a low risk for virological...